Abstracts tagged "remission"

Abstract Number: 1049 • 2012 ACR/ARHP Annual Meeting
The Prevalence of the Ultrasonographic Positive Power Doppler Synovitis Is High and Predicts the Risk of Relapse and Structural Progression in Rheumatoid Arthritis in Clinical Remission: A Systematic Literature Review and Meta Analysis
Huong Nguyen¹, Adeline Ruyssen-Witrand¹, Arnaud L. Constantin¹, Violaine Foltz², Frédérique Gandjbakhch³ and Alain G. Cantagrel¹, ¹Rheumatology, Purpan University Hospital, Toulouse, France, ²APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ³Department of Rheumatology, APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France
Background/Purpose: Ultrasonography (US) can detect synovitis in patients with rheumatoid arthritis (RA) more sensitively than clinical examination either in active disease or in remission.1, 2…
Abstract Number: 1011 • 2012 ACR/ARHP Annual Meeting
Structural Damage Is Reduced by Early Achievement of Clinical Remission
Paul Emery¹, Vibeke Strand², Andrew S. Koenig³, Ronald Pedersen³ and Eustratios Bananis⁴, ¹Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²Biopharmaceutical Consultant, Portola Valley, CA, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: The importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent structural damage is established.1 The objective of this…
Abstract Number: 809 • 2012 ACR/ARHP Annual Meeting
Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis
Ryusuke Yoshimi¹, Maasa Hama¹, Daiga Kishimoto¹, Reikou Watanabe¹, Takeaki Uehara², Yukiko Asami¹, Atsushi Ihata¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan
Background/Purpose: Although clinical remission is an agreeable goal of treatment in rheumatoid arthritis (RA), the definition is still controversial. Indeed, progressive structural damage is often…
Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Thomas J. A. Lehman¹, Emily Baird², Anusha Ramanathan³, Risa Alperin³, Emma J. MacDermott³, Alexa B. Adams³, Laura V. Barinstein³ and Lakshmi N. Moorthy⁴, ¹Chief Div Ped Rheum PTD, Hosp for Special Surgery, New York, NY, ²Hospital for Special Surgery, NY, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ
Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…
Abstract Number: 461 • 2012 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study
J.V. Tovar Beltrán¹, M.A. Guzmán Úbeda², I. Mateo Bernardo³, Rosario García-Vicuña⁴, M. Rodríguez-Gómez⁵, M. Belmonte-Serrano⁶, C. Marras⁷, E. Loza Cortina⁸, E. Pérez Pampin⁹, V. Vila Fayos¹⁰, A.B. Romero Silva¹¹ and A. Balsa¹², ¹Hospital General Universitario de Elche, Alicante, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario La Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁶Hospital General de Castellón, Castellón, Spain, ⁷Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁸Hospital de Navarra, Navarra, Spain, ⁹Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰Hospital Comarcal de Vinaroz, Castellón, Spain, ¹¹Roche Farma, Madrid, Spain, ¹²Rheumatology, Hospital La Paz, Madrid, Spain
Background/Purpose: Currently, the available evidence about tocilizumab (TCZ) use for the treatment of rheumatoid arthritis (RA) in daily clinical practice is scarce. This study was…
Abstract Number: 371 • 2012 ACR/ARHP Annual Meeting
Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Takahiko Sugihara¹, Tatsuro Ishizaki², Tadashi Hosoya¹, Shoko Iga¹, Waka Yokoyama¹, Fumio Hirano¹, Nobuyuki Miyasaka³ and Masayoshi Harigai⁴, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical…
Abstract Number: 109 • 2012 ACR/ARHP Annual Meeting
Does Joint Sonography Really Add Clinically Important Information Beyond Clinical Joint Examination?
Miriam Gärtner¹, Helga Radner², Gabriela Supp², Peter Mandl³, Daniel Aletaha¹, Klaus P. Machold⁴ and Josef S. Smolen⁵, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁵Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Sonographic assessment of joint activity in patients with rheumatoid arthritis (RA) is considered to be more sensitive than the respective clinical assessment. However, this…
Abstract Number: L7 • 2012 ACR/ARHP Annual Meeting
Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Bruno Fautrel¹, Thao Pham², Florence Tubach³, Toni Alfaiate⁴, Jacques Morel⁵, Emmanuelle Dernis⁶, Xavier J. Puechal⁷, Philippe Gaudin⁸ and Xavier Mariette⁹, ¹Rheumatology, UPMC - Paris 6 University, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Centre Hospitalier, Le Mans, France, ⁷Le Mans Hospital, Le Mans, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: Step-down therapeutic strategies are often considered in established rheumatoid arthritis (RA) once remission is achieved but are associated with a potential risk of relapse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.